Claritas Pharmaceuticals, Inc. (CLAZF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share. Beta 1.64: the stock has moved about 64% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerClaritas Pharmaceuticals, Inc. (CLAZF) trades at $0.0001. Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for unmet medical needs. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for CLAZF: CLAZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Claritas Pharmaceuticals, Inc. (CLAZF) Healthcare & Pipeline Overview
Claritas Pharmaceuticals, Inc. is a clinical-stage biotechnology firm established in 2014, specializing in developing and commercializing medical therapies for significant unmet patient needs. Operating from San Rafael, California, the company focuses on advancing its pipeline to address critical health challenges within the pharmaceutical sector.
What Is the Investment Thesis for CLAZF?
Claritas Pharmaceuticals, Inc. presents an investment profile centered on its clinical-stage pipeline targeting unmet medical needs within the biotechnology sector. As a company focused on developing novel therapies, its primary value drivers are the successful progression of its drug candidates through clinical trials and eventual regulatory approval. Given its current stage, the company's valuation is heavily influenced by the potential market size of its therapeutic areas and the probability of success for its pipeline assets. Growth catalysts are intrinsically linked to positive clinical trial results, which could significantly de-risk its programs and attract further investment or partnership opportunities. Key milestones would include advancing candidates into later-stage trials (e.g., Phase 2 or Phase 3) and the announcement of favorable data. The company's rebranding in April 2021 signifies a potential strategic realignment or renewed focus, which could underpin future development efforts. However, as a clinical-stage entity with a market capitalization of $0.00B and a P/E of 0.00, it carries substantial inherent risks, including clinical trial failures, regulatory hurdles, and the need for significant future capital raises. Its OTC Other listing further introduces liquidity and disclosure challenges for investors.
Based on FMP financials and quantitative analysis
CLAZF Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or pre-revenue stage company.
- P/E Ratio: 0.00, reflecting the company's current lack of profitability or significant earnings.
- Beta: 1.64, suggesting higher volatility compared to the broader market.
- Employee Count: 3, indicating a very lean operational structure for a clinical-stage pharmaceutical company.
- Dividend Yield: None, consistent with a growth-oriented, clinical-stage biotechnology firm reinvesting all capital into R&D.
Who Are CLAZF's Competitors?
CLAZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.27 | +1.17% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLAZF's Key Strengths?
Focus on unmet medical needs, addressing areas with high demand.
- Clinical-stage pipeline with potential for novel therapies.
- Lean operational structure with a small, focused team.
- Rebranding in 2021 suggests renewed strategic focus.
What Are CLAZF's Weaknesses?
Very small employee count (3), indicating limited internal resources.
- Clinical-stage company with no current revenue or profitability (P/E 0.00).
- Market capitalization of $0.00B, suggesting early development or micro-cap status.
- OTC Other listing, implying lower liquidity and disclosure compared to major exchanges.
What Are the Key Risks for CLAZF?
Financial-distress signal — its Altman Z-Score of -8.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failures, common for clinical-stage biotechs.
- Significant capital requirements and potential for future shareholder dilution.
- Intense competition from well-funded pharmaceutical companies.
- Regulatory hurdles and delays in obtaining drug approvals.
- Low liquidity and limited disclosure associated with OTC Other listing.
What Are CLAZF's Competitive Advantages?
- Proprietary intellectual property (patents) protecting its drug candidates.
- Specialized scientific expertise in its chosen therapeutic areas.
- Regulatory approvals for its drug candidates, creating barriers to entry for competitors.
- Clinical trial data and results, which are difficult and costly to replicate.
What Does CLAZF Do?
Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. The company's strategic focus is on identifying and developing innovative treatments for conditions where existing options are limited or inadequate, aiming to improve patient outcomes and quality of life. Established in 2014, the company initially operated under the name Kalytera Therapeutics, Inc. This foundational period involved early-stage research and development efforts, laying the groundwork for its current pipeline. In a significant corporate evolution, the company underwent a rebranding in April 2021, officially changing its name to Claritas Pharmaceuticals, Inc. This rebranding marked a strategic pivot or a clearer articulation of its mission and therapeutic focus. Its corporate headquarters are located in San Rafael, California, serving as the central hub for its operations, which include managing its clinical development programs and strategic partnerships. As a clinical-stage company, Claritas Pharmaceuticals, Inc. is primarily engaged in the rigorous process of bringing potential new drugs through various phases of clinical trials, from initial safety assessments to efficacy studies in patient populations. This involves substantial investment in research, regulatory compliance, and scientific expertise, all geared towards eventually securing regulatory approvals for its therapeutic candidates. The company's small employee base of three individuals suggests a lean operational model, likely relying on outsourced research, contract manufacturing organizations, and strategic collaborations to advance its pipeline. This structure is common among early-stage biotechnology firms, allowing for flexibility and focused resource allocation on core R&D activities. The ultimate goal is to address critical medical gaps and deliver novel pharmaceutical solutions to the market.
What Products and Services Does CLAZF Offer?
- Develops and commercializes medical therapies.
- Focuses on addressing significant unmet patient needs.
- Operates as a clinical-stage specialty pharmaceutical entity.
- Conducts research and development for new drug candidates.
- Manages clinical trials for its therapeutic pipeline.
- Aims to introduce novel treatments to the market.
- Headquartered in San Rafael, California.
How Does CLAZF Make Money?
- Primarily focused on research and development of drug candidates.
- Future revenue generation is contingent on successful clinical trials, regulatory approvals, and commercialization of therapies.
- Potential for revenue through licensing agreements, milestone payments, and royalties from partnerships.
- Currently relies on capital raises to fund its operations and R&D activities.
What Industry Does CLAZF Operate In?
Claritas Pharmaceuticals, Inc. operates within the highly specialized and capital-intensive biotechnology industry, a segment of the broader healthcare sector. This industry is characterized by long development cycles, significant R&D expenditures, and high regulatory hurdles. The company's focus on "unmet medical needs" aligns with a major trend in pharmaceuticals, where innovation is driven by addressing conditions lacking effective treatments. The competitive landscape is intense, featuring both large pharmaceutical companies with vast resources and numerous smaller, clinical-stage biotechs vying for breakthrough discoveries. Claritas, with its lean structure and clinical-stage pipeline, positions itself as an innovator seeking to carve out niche markets by developing novel therapies. Its success will depend on its ability to navigate the complex clinical trial process, secure intellectual property, and differentiate its potential products in a crowded market. The industry is also subject to evolving scientific understanding and technological advancements, which can rapidly shift therapeutic paradigms.
Who Are CLAZF's Key Customers?
- Ultimately, patients suffering from conditions with unmet medical needs.
- Healthcare providers (doctors, hospitals) who prescribe and administer treatments.
- Pharmaceutical distributors and pharmacies.
- Potential pharmaceutical partners for licensing or co-development agreements.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Claritas Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Rafael, US. The company is led by CEO Robert Farrell. CLAZF has traded publicly since 2016.
Forward Outlook
Wall Street analysts project Claritas Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.29.
Financial Health
Claritas Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.30 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is 40.3%, showing how much profit it generates from its asset base. CLAZF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~21.10x. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching.
CLAZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CLAZF Latest News
No recent news available for CLAZF.
CLAZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CLAZF.
Price Targets
Wall Street price target analysis for CLAZF.
CLAZF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CLAZF; grades run from A+ (80-100) to F (below 30).
CLAZF OTC Market Information
The OTC Other tier, also known as the Pink Sheets, is the lowest and most speculative tier of the over-the-counter market. Unlike companies listed on major exchanges such as NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, companies on OTC Other have minimal to no disclosure requirements. This tier is not a reporting exchange and includes companies that may not be current in their reporting or have limited public information. This contrasts sharply with the robust regulatory oversight and transparency mandated for companies on national exchanges, which provide investors with standardized, timely financial data and greater liquidity.
- OTC Tier: OTC Other
- Limited public information and disclosure, making due diligence challenging.
- Significantly lower liquidity and wider bid-ask spreads compared to major exchanges.
- Increased susceptibility to market manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable price quotes and executing trades efficiently.
- Potential for delisting or further restrictions if disclosure status remains unknown or inadequate.
- Verify the company's current financial statements and audit reports, if any are available.
- Research any available news, press releases, or corporate filings from reliable sources.
- Assess the company's business model, pipeline, and intellectual property claims thoroughly.
- Investigate the background and track record of management and board members.
- Understand the specific regulatory environment and clinical trial progress for its therapies.
- Evaluate the company's capital structure, outstanding shares, and potential for dilution.
- Consult with a financial advisor experienced in OTC markets.
- Established in 2014, indicating a history beyond a recent shell company.
- Rebranded in April 2021, suggesting active corporate management and strategic intent.
- Identified headquarters location in San Rafael, California.
- Focus on a specific industry (Biotechnology) and mission (unmet medical needs).
Common Questions About CLAZF (Healthcare)
What are the implications of Claritas Pharmaceuticals, Inc. trading on the OTC Other market?
Trading on the OTC Other market, also known as the Pink Sheets, carries several implications for Claritas Pharmaceuticals, Inc. and its investors.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- All information is derived directly from the provided source data.